Skip to content

Metabolomics-based Markers of Mitochondrial Reverse Electron Transport in Patients with Sepsis induced Myocardial Dysfunction: A Cohort Study

Metabolomics-based Markers of Mitochondrial Reverse Electron Transport in Patients with Sepsis induced Myocardial Dysfunction: A Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088246
Enrollment
Unknown
Registered
2024-08-14
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Healthy Control Group:None
Sepsis induced Myocardial Dysfunction Group:None
Sepsis non cardiac dysfunction group:None

Sponsors

The Second Hospital & Clinical Medical School, Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 100 Years

Inclusion criteria

Inclusion criteria: Sepsis patients (aged = 14 years) who meet the criteria of Sepsis 3.0 in the Intensive Care Medicine Department of Lanzhou University Second Hospital.

Exclusion criteria

Exclusion criteria: 1) Individuals with acute myocardial infarction, cardiac surgery, or heart function grade IV within the past month; 2) End stage renal disease requiring renal replacement therapy; 3) Patients with severe liver dysfunction (Child Pugh C grade or above), 4) Individuals with severe neurological disorders (such as Parkinson's disease, Alzheimer's disease); 5) Individuals who have undergone major surgery or severe trauma within the past month prior to enrollment; 6) Diagnosed with sepsis for more than 24 hours or those who have undergone blood purification or ECMO treatment before enrollment (excluding those who require in vitro support due to the condition after sample retention); 7) Individuals with active tumors or autoimmune diseases (such as those receiving radiation therapy, chemotherapy, long-term or extensive hormone therapy); 8) Within one month before enrollment, take antioxidants such as vitamin C, vitamin E, coenzyme Q10, glutathione, or trimetazidine, which interfere with the results of metabolomics analysis (excluding those who use the above drugs due to illness needs after sample retention); 9) Pregnant or lactating women; 10) Those who refuse to participate in this study and have incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Metabolomics;H2O2;MDA;

Secondary

MeasureTime frame
Changes in mitochondrial RET related markers during ICU transfer with improvement;

Countries

CHINA

Contacts

Public ContactNannan He

The Second Hospital & Clinical Medical School, Lanzhou University

295028434@qq.com+86 139 1925 4254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026